Role of the immune system and immunological circuits in psoriasis

Giornale Italiano di Dermatologia e Venereologia

Volumn 146, Issue 1, 2011, Pages 17-30

  Jabbari, A ^a,b   Johnson Huang, L M ^b   Krueger, J G ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cytokines; Dendritic cells; Immunologic factors; Psoriasis; T lymphocytes subsets

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ETANERCEPT; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; TUMOR NECROSIS FACTOR; USTEKINUMAB;

ALLELE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; ENDOCYTOSIS; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; IMMUNE SYSTEM; IMMUNOGENETICS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSTIMULATION; LANGERHANS CELL; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PSORIASIS VULGARIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL;

EID: 79955765713     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:J314-21.
2. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
3. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quin tanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150:917-28. (Pubitemid 38903524)
4. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535-46. (Pubitemid 350087600)
5. Andressen C, Henseler T. [Inheritance of psoriasis. Analysis of 2035 family histories]. Hautarzt 1982;33:214-7.
6. Watson W, Cann HM, Farber EM, Nall ML. The genetics of psoriasis. Arch Dermatol 1972;105:197-207.
7. Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med 1972;287:738-40.
8. Veal CD, Capon F, Allen MH, Heath EK, Evans JC, Jones A et al. Family-based analysis using a dense single-nucleotide polymor phism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 2002;71:554-64. (Pubitemid 34970126)
9. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006;78:827-51.
10. Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 1997;109:183-6.
11. Mallon E, Bunce M, Savoie H, Rowe A, Newson R, Gotch F et al. HLA-C and guttate psoriasis. Br J Dermatol 2000;143:1177-82. (Pubitemid 32052752)
12. Bowcock AM, Krueger JG. Getting under the skin: The immuno genetics of psoriasis. Nat Rev Immunol 2005;5:699-711. (Pubitemid 43090738)
13. Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985-90.
14. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204.
15. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4:e1000041.
16. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R et al. Polymorphisms of the IL12B and IL23R genes are associ ated with psoriasis. J Invest Dermatol 2008;128:1653-61. (Pubitemid 351847381)
17. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28.
18. Zervou MI, Goulielmos GN, Castro-Giner F, Tosca AD, Krueger-Krasagakis S. STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum Immunol 2009;70:738-41.
19. Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010;42:991-5.
20. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010;42:996-9.
21. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008;8:935-47.
22. Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human Langerhans cells induce distinct IL-22-producing CD4+T cells lacking IL-17 production. Proc Natl Acad Sci U S A 2009;106:21795-800.
23. Ito T, Amakawa R, Inaba M, Hori T, Ota M, Nakamura K et al. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 2004;172:4253-9. (Pubitemid 38375238)
24. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macro phages. J Clin Invest 2007;117:2517-25. (Pubitemid 47494353)
25. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129:79-88.
26. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008;29:497-510.
27. Larregina AT, Falo LD. Changing paradigms in cutaneous im munology: adapting with dendritic cells. J Invest Dermatol 2005;124:1-12. (Pubitemid 40100942)
28. Kaplan DH, Kissenpfennig A, Clausen BE. Insights into Langerhans cell function from Langerhans cell ablation models. Eur J Immunol 2008;38:2369-76.
29. Bobr A, Olvera-Gomez I, Igyarto BZ, Haley KM, Hogquist KA, Kaplan DH. Acute ablation of Langerhans cells enhances skin immune responses. J Immunol 2010;185:4724-8.
30. Waithman J, Allan RS, Kosaka H, Azukizawa H, Shortman K, Lutz MB et al. Skin-derived dendritic cells can mediate deletional tolerance of class I-restricted self-reactive T cells. J Immunol 2007;179:4535-41.
31. Hemmi H, Yoshino M, Yamazaki H, Naito M, Iyoda T, Omatsu Y et al. Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-beta1-dependent cells. Int Immunol 2001;13:695-704. (Pubitemid 32427872)
32. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T et al. IL-22-producing "T22" T cells account for up-regulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009;123:1244-52 e2.
33. Bieber T, Ring J, Braun-Falco O. Comparison of different methods for enumeration of Langerhans cells in vertical cryosections of human skin. Br J Dermatol 1988;118:385-92.
34. Ashworth J, Mackie RM. A quantitative analysis of the Langerhans cell in chronic plaque psoriasis. Clin Exp Dermatol 1986;11:594-9. (Pubitemid 17174556)
35. Cumberbatch M, Singh M, Dearman RJ, Young HS, Kimber I, Griffiths CE. Impaired Langerhans cell migration in psoriasis. J Exp Med 2006;203:953-60.
36. Shaw FL, Cumberbatch M, Kleyn CE, Begum R, Dearman RJ, Kimber I et al. Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. J Invest Dermatol 2010;130:1940-2.
37. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43. (Pubitemid 41002916)
38. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A et al. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008;3:e2737.
39. van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004;122:51-60.
40. Schmid P, Itin P, Cox D, McMaster GK, Horisberger MA. The type I interferon system is locally activated in psoriatic lesions. J Interferon Res 1994;14:229-34.
41. Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 1995;43:47-52.
42. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon- alpha therapy for hepatitis C. Clin Exp Dermatol 2000;25:351-2. (Pubitemid 30670597)
43. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol 1991;125:463-5.
44. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199:731-6. (Pubitemid 38316440)
45. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Ba zan F et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial an tigens. J Exp Med 2001;194:863-9. (Pubitemid 32983021)
46. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule rec ognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001;31:3388-93. (Pubitemid 33100532)
47. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-23.
48. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.
49. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang Y, Homey B et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-9. (Pubitemid 47525141)
50. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009;206:1983-94.
51. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-5.
52. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV et al. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci U S A 2007;104:18631-5. (Pubitemid 350210748)
53. Zaba L, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94.
54. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduc tion with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005;102:19057-62. (Pubitemid 43049565)
55. Serbina NV, Salazar-Mather TR Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune de fense against bacterial infection. Immunity 2003;19:59-70. (Pubitemid 36859901)
56. Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tern) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 2007;5:27.
57. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005;102:2075-80. (Pubitemid 40262014)
58. Haider A, Lowes M, Suárez-Fariñas M, Zaba L, Cardinale I, Khatcherian A et al. Identification of cellular pathways of "type 1", Th 17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008;180:1913-20.
59. Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Lowes MA. Effective narrow-band UVB radiation therapy suppresses the il-23/il-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010 [E-pub 17 June 2010].
60. Wang F, Lee E, Lowes MA, Haider AS, Fuentes-Duculan J, Abello MV et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 2006;126:1590-9.
61. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008;181:7420-7.
62. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Johnson-Huang LM, Nograles KE, White TR et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol 2010;125:1261-8 e9.
63. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11.
64. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008;181:4733-41.
65. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
66. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008;226:132-46.
67. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708. (Pubitemid 34556153)
68. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al. Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris. J Exp Med 2004;199:125-30. (Pubitemid 38076484)
69. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008;226:112-31.
70. Zhou L, Ivanov, II, Spolski R, Min R, Shenderov K, Egawa T et al. IL-6 programs T(H)-17 cell differentiation by promoting sequen tial engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-74. (Pubitemid 47300011)
71. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121-33.
72. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzen berger P et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194:519-27. (Pubitemid 32835046)
73. Kelly MN, Kolls JK, Happel K, Schwartzman JD, Schwarzenberger P, Combe C et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005;73:617-21.
74. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S et al. IL-17 plays an important role in the development of experimen tal autoimmune encephalomyelitis. J Immunol 2006;177:566-73. (Pubitemid 43939170)
75. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-8.
76. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 pro duction from activated T cells is required for the spontaneous de velopment of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003;100:5986-90. (Pubitemid 36576918)
77. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y et al. Increased expression of interleukin 17 in inflammatory bowel dis ease. Gut 2003;52:65-70. (Pubitemid 36020767)
78. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-4.
79. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009;54:99-105.
80. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15.
81. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD et al. Development, cytokine profile and func tion of human interleukin 17-producing helper T cells. Nat Immu nol 2007;8:950-7. (Pubitemid 47300009)
82. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9. (Pubitemid 28452327)
83. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373-83.
84. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Media tors Inflamm 2005;2005:273-9. (Pubitemid 41577417)
85. Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK et al. Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. J Immunol 2010;185:5688-91.
86. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092-102.
87. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopou los K, Collins M et al. Interleukin (IL)-22 and IL-17 are coex pressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9. (Pubitemid 44498362)
88. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
89. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J In vest Dermatol 1993;101:701-5. (Pubitemid 23322027)
90. Lew W, Lee E, Krueger JG. Psoriasis genomics: analysis of pro inflammatory (type T) gene expression in large plaque (West ern) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol 2004;150:668-76. (Pubitemid 38586217)
91. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-32. (Pubitemid 30408849)
92. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol 2010;107:1-29.
93. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010;32:17-31.
94. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150:407-15.
95. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004;21:241-54.
96. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000;275:31335-9.
97. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009;457:722-5.
98. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008;14:282-9. (Pubitemid 351347912)
99. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002;168:5397-402.
100. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857-63.
101. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10:864-71.
102. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008;14:275-81.
103. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 pro vides protection to hepatocytes during acute liver inflammation. Immunity 2007;27:647-59. (Pubitemid 47615503)
104. Wilson MS, Feng CG, Barber DL, Yarovinsky F, Cheever AW, Sher A et al. Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol 2010;184:4378-90.
105. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 2010;163:1282-90.
106. Lo YH, Torii K, Saito C, Furahashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci 2010;58:225-7.
107. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008;118:597-607. (Pubitemid 351206549)
108. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40. (Pubitemid 46233421)
109. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87:523-36.
110. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:3573-85.
111. Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epider mal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993;94:354-62. (Pubitemid 23337840)
112. Bradley J. TNF-mediated inflammatory disease. J Pathol 2007;214:149-60. (Pubitemid 351160153)
113. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of inter cellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989;20:617-29. (Pubitemid 19091260)
114. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K. Produc tion of interleukin-8 by human dermal fibroblasts and keratino cytes in response to interleukin-1 or tumour necrosis factor. Im munology 1989;68:31-6. (Pubitemid 19236065)
115. Partridge M, Chantry D, Turner M, Feldmann M. Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines. J Invest Dermatol 1991;96:771-6.
116. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing hu man T helper cells. Nat Immunol 2007;8:942-9. (Pubitemid 47300008)
117. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I et al. Integrative Responses to IL-17 and TNF-alpha in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis. J Invest Dermatol 2010 [E-pub 18 November 2010].
118. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically de creases the clinical activity of psoriasis lesions. J Am Acad Der matol 2000;42:829-30. (Pubitemid 30252891)
119. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42. (Pubitemid 39278071)
120. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C et al. Infliximab induction and maintenance therapy for moderate-to-se vere psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74. (Pubitemid 41443403)
121. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22. (Pubitemid 37448924)
122. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP et al. Efficacy and safety results from the randomized con trolled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66. (Pubitemid 351239154)
123. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15. (Pubitemid 350298146)
124. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized con trolled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606. (Pubitemid 44436647)
125. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y et al. Efficacy and safety of ustekinumab, a human interleu kin-12/23 monoclonal antibody, in patients with psoriasis: 76- week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)